Incyte Corporation vs Alliant Energy Corporation — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Alliant Energy Corporation trades at $65.85 (market cap $16.99B). The key difference: Incyte Corporation is the larger of the two by market cap, and Alliant Energy Corporation pays a 3.27% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Alliant Energy Corporation for 64 Days on average.
| INCY | LNT | |
|---|---|---|
Market Cap | $22.85B | $16.99B |
Volume | 1,927,029 | 2,488,387 |
Sector | Health | Utilities |
52-Week High | $129.93 | $78.03 |
52-Week Low | $83.80 | $63.21 |
Typical Hold Time | 33 Days | 64 Days |
Enterprise Value | $18.35B | $29.08B |
Dividend Yield | — | 3.27% |
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Alliant Energy (LNT) trades at $65.50, up 0.44% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with Q2 2026 EPS beating expectations at $0.65 and consistent revenue growth to $4.36B in 2025. Analyst consensus is positive with a $77.00 price target and 52% buy ratings. Recent institutional activity includes significant purchases by California State Teachers Retirement System and Nykredit A/S.
LNT presents a compelling investment case with stable utility operations, 23-year dividend growth, and a $13.4B capital investment plan supporting 5-7% earnings growth. Key risks include rising debt levels (debt-to-asset ratio increased to 48.48% in 2025) and sensitivity to interest rate changes. The stock offers defensive value with current momentum favoring upside toward analyst targets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →